A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study

[11] Falcone J(2003)Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase II trial comparing single does of palonosetron with ondansetron Ann Oncol 14 1570-1577

[12] Bymaster FP(2004)Incidence of chemotherapy-induced nausea and emesis after modern anti-emetics: perception versus reality Cancer 100 2261-2268

[13] Falcone JF(1997)Olanzapine Br J Hosp Med 58 443-445

[14] Bauzon D(2003)The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study group J Clin Oncol 21 4112-4119

[15] Cleeland CS(1996)Comparison of granisetron versus ondansetron versus tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer; a randomized controlled trial Cancer 77 941-948

[16] Mendoza TR(2003)Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents J Support Oncol 1 89-103

[17] Wang XS(2004)Inhibiting substance P pathway for prevention of chemotherapy-induced emesis: preclinical data, clinical trials of neurokinin-1 receptor antagonists Support Cancer Ther 1 89-96

[18] Eisenberg P(2006)Palonosetron: a second generation 5-hydroxytryptamine receptor antagonist Future Oncol 2 591-602

[19] Figueroa-Vadillo J(2005)A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting Support Care Cancer 13 529-534

[20] Zamora R(1999)Reduction of cisplatin-induced emesis by a selective neurokin-1 receptor antagonist N Engl J Med 340 190-195

[11] Falcone J(2003)Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase II trial comparing single does of palonosetron with ondansetron Ann Oncol 14 1570-1577

[12] Bymaster FP(2004)Incidence of chemotherapy-induced nausea and emesis after modern anti-emetics: perception versus reality Cancer 100 2261-2268

[13] Falcone JF(1997)Olanzapine Br J Hosp Med 58 443-445

[14] Bauzon D(2003)The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study group J Clin Oncol 21 4112-4119

[15] Cleeland CS(1996)Comparison of granisetron versus ondansetron versus tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer; a randomized controlled trial Cancer 77 941-948

[16] Mendoza TR(2003)Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents J Support Oncol 1 89-103

[17] Wang XS(2004)Inhibiting substance P pathway for prevention of chemotherapy-induced emesis: preclinical data, clinical trials of neurokinin-1 receptor antagonists Support Cancer Ther 1 89-96

[18] Eisenberg P(2006)Palonosetron: a second generation 5-hydroxytryptamine receptor antagonist Future Oncol 2 591-602

[19] Figueroa-Vadillo J(2005)A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting Support Care Cancer 13 529-534

[20] Zamora R(1999)Reduction of cisplatin-induced emesis by a selective neurokin-1 receptor antagonist N Engl J Med 340 190-195